3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

The article spotlights healthcare dividend strategies, led by AbbVie after Humira’s patent expiration, with earnings growth expected around 12%–13% annually and an initial ~2.5% yield that is covered by ~48% of estimated 2026 earnings. It also highlights Medtronic’s steady dividend (49 consecutive years) with payout ~48% of 2026 earnings and potential upside from robotics-assisted surgery (Hugo system), while Bristol Myers Squibb offers a higher ~4.3% yield but faces a patent cliff and expected long-term earnings decline (~1% annualized), though shares trade at ~9x forward earnings and dividends are covered at ~40% of 2026 earnings.

Analysis

This is less a sector event than a quality screen for defensive healthcare capital. The market mechanism is straightforward: when investors want income, they usually overpay for headline yield and underappreciate forward FCF durability; that favors names with visible reinvestment runway over pure yield plays. On that basis, ABBV is the cleaner compounder, while BMY is the classic value trap risk if the pipeline fails to offset the patent overhang on schedule.

The second-order dynamic is competitive spending pressure in pharma and medtech. BMY must fund an unusually heavy internal R&D cadence to defend revenue, which can keep the stock cheap for longer even if the dividend is safe; ABBV’s cleaner cash generation should support a higher multiple as long as growth stays mid-teens. In devices, MDT’s upside is really about whether Hugo becomes a budget-line item rather than a science story — if hospital capex gets tighter, adoption can still occur, but the premium multiples on incumbents like ISRG become more fragile.

Contrarian view: the consensus is already treating dividends as downside protection, but the real differentiator is dividend growth, not yield. If AbbVie’s post-Humira franchise decelerates, the current de-risked narrative compresses quickly; if BMY shows one or two pipeline wins, the stock can rerate hard because expectations are so low. Near term, this is mostly a months-long relative-value setup rather than a broad sector catalyst.

Key Decisions for Investors

• Long ABBV / short BMY for the next 3-6 months: same income-investor cohort, but ABBV has better earnings visibility and less financing risk to defend the payout; target modest multiple expansion on ABBV and keep a stop if BMY pipeline sentiment improves materially.
• Add MDT only on pullbacks, with a 6-12 month horizon: the valuation can re-rate if Hugo bookings and procedure adoption show up in guides; falsify the thesis if robotic utilization remains incremental rather than competitive versus ISRG.
• Use BMY as a source of funds rather than a core long until the next pipeline readout: the risk/reward is asymmetric only if you believe at least one late-stage asset de-risks revenue replacement within 12-18 months.
• If you want a cleaner defensive healthcare basket, favor ABBV/MDT over generic healthcare ETFs (XLV/XBI) for the next earnings cycle; the article’s setup is idiosyncratic, not a broad sector beta call.
• Watch for any guide-down in ABBV’s post-Humira growth or a negative update on BMY patent replacement cadence; either would invalidate the relative-value long/short and argue for flattening the trade.